The endocrine disease drug developer completed a series B round that included $125m from former parent company Ascendis.
Biopharmaceutical company Ascendis Pharma has invested $12.5m in China-based endocrine drug developer Visen Pharmaceuticals through a $150m series B round that closed on Saturday.
Sequoia China led the round, which included Pivotal BioVenture Partners China – a vehicle for property developer Nan Fung – as well as OrbiMed, Sherpa Healthcare Partners, Cormorant, HBM Healthcare Investments, Logos Capital, CDG Capital, Vivo Capital and Sofinnova Investments.
Visen is developing treatments for diseases affecting the endocrine system, a network of glands that secrete…
